Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021
Helsinki, Finland – Nasdaq announced today the results of the…
Nanoform welcomed as a new member of Pharma Industry Finland (PIF)
Nanoform has been accepted as a new member of Pharma…
First dosing of nanoformed drug successfully accomplished
Press Release Nanoform Finland Plc December 21st, 2020 at 09.00…
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Inside information Nanoform Finland Plc December 17, 2020 at 7:15 p.m.…
Notification of major shareholdings according to Nanoform’s Articles of Association
PRESS RELEASE Nanoform Finland Plc December 8th, 2020 06.05 p.m.…
Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)
PRESS RELEASE Nanoform Finland Plc December 2nd, 2020 4 p.m.…
Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time
COMPANY RELEASE Nanoform Finland Plc, Interim Report January – September…
Nanoform launches technology for biologics and sets new near-term business target for 2021
Inside information Nanoform Finland Plc November 27th, 2020 at 07:50…
Invitation to presentation of Nanoform’s Q3 Report on November 27
PRESS RELEASE Nanoform Finland Plc November 16, 2020 11:00 a.m.…
Nanoform to present at Avanza Börsdag on November 18
PRESS RELEASE Nanoform Finland Plc November 11th, 2020 11:00 a.m.…
Amplifying Scientific Innovation Podcast
In Episode 5, Season 2 of the Amplifying Scientific Innovation…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company Announcement October 23rd, 2020 at 7:00 p.m. Finnish time…
Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule
Inside information Nanoform Finland Plc October 20th, 2020 at 5:15…
Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade
Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade Nanoform…
Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs
COMPANY RELEASE September 2, 2020 at 03:00 p.m. Finnish time …
Nanoform expands global commercial team with US appointments
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle…
Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020
COMPANY RELEASE September 1, 2020 at 1:00 p.m. Finnish time…
NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST
COMPANY RELEASE NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT,…
Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC
The shareholders of Nanoform Finland Plc (business ID: 2730572-8) are…
Nanoform convenes EGM to elect Cynthia Schwalm as board member
COMPANY RELEASE August 6, 2020 9:10 am Helsinki time Helsinki,…
Nanoform’s positive commercial momentum continues
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company Announcement
June 25, 2020 at 4:00 p.m. Finnish time
Nanoform Finland Plc appoints Peter Hänninen as General Counsel
Press Release June 15, 2020 at 8:00 a.m. Finnish time…
Nanoform Finland Plc – Manager’s transactions – Edward Hæggström
Nanoform Finland Plc – Manager’s transactions – June 10, 2020…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Nanoform Finland Plc – Manager’s transactions – June 10, 2020…
Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN…
Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden
Nanoform announces a fixed subscription price and publishes a prospectus…
Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille
Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth…
Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden
Nanoform intends to launch an initial public offering and dual…
Nanoform awarded GMP certification
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine…
Nanoform and Orion collaborate on next-generation drug development
Nanoform and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform’s award-winning CESS® technology to new chemical entities.